Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | SGMS1 | Q86VZ5 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9927443 | 0.88 | TPSAB1 (0.67) | TPSAB1PRMT1AKR1C3ALDH1A1CYP19A1 | |
| SCHEMBL29259793 | 0.84 | ALDH1A1 (0.74) | TPSAB1KMT2AAKR1C3ALDH1A1SGMS1 | |
| SCHEMBL9754552 | 0.83 | MEN1 (0.84) | MEN1KMT2APRMT1AKR1C3ALDH1A1 | |
| SCHEMBL11105195 | 0.83 | ALDH1A1 (0.64) | TPSAB1KMT2AAKR1C3ALDH1A1TBXA2R | |
| SCHEMBL1287281 | 0.82 | PRMT1 (0.83) | MEN1KMT2APRMT1ALDH1A1TP53 | |
| SCHEMBL16863964 | 0.81 | TPSAB1 (0.59) | TPSAB1ALDH1A1GAANPY1RNPY5R | |
| SCHEMBL13889020 | 0.80 | ALDH1A1 (0.69) | TPSAB1ALDH1A1TP53GAANPY1R | |
| SCHEMBL4617723 | 0.80 | AKR1C3 (0.69) | MEN1KMT2APRMT1AKR1C3ALDH1A1 | |
| SCHEMBL30270468 | 0.79 | ALDH1A1 (0.64) | TPSAB1ALDH1A1GAANPY1RNPY5R | |
| SCHEMBL26212898 | 0.79 | ALDH1A1 (0.64) | TPSAB1ALDH1A1GAANPY1RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | TPSAB1 869/4885MEN1 4622/4885KMT2A 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.